{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:33:36Z","timestamp":1790930016339,"version":"4.1.0"},"reference-count":425,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.pharmthera.2004.10.007","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T08:25:22Z","timestamp":1103703922000},"page":"267-310","source":"Crossref","is-referenced-by-count":197,"title":["Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease"],"prefix":"10.1016","volume":"105","author":[{"given":"Kui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bastia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwarzschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2004.10.007_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0031-6989(87)90085-3","article-title":"Adenosine modulates the dopaminergic function in the nigro-striatal system by interacting with striatal dopamine dependent adenylate cyclase","volume":"19","author":"Abbracchio","year":"1987","journal-title":"Pharmacol Res Commun"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0922-4106(92)90010-S","article-title":"Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of adenosine A1 but not A2 receptors","volume":"227","author":"Abbracchio","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2004.06.003","article-title":"Neuroprotective effect of l-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease","volume":"64","author":"Agnati","year":"2004","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0006-8993(89)90251-5","article-title":"Subchronic cocaine treatment enhances cocaine-induced dopamine efflux-studies by in vivo microdialysis","volume":"490","author":"Akimoto","year":"1989","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1212\/WNL.42.4.733","article-title":"Alternative excitotoxic hypotheses","volume":"42","author":"Albin","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib7","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1523\/JNEUROSCI.20-15-05848.2000","article-title":"Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist","volume":"20","author":"Aoyama","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.410100602","article-title":"A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease","volume":"10","author":"Appel","year":"1981","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib9","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/01.STR.0000068170.80517.B3","article-title":"Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience","volume":"34","author":"Aronowski","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib10","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1212\/01.WNL.0000095213.86899.21","article-title":"Caffeinated clues from epidemiology of Parkinson's disease","volume":"61","author":"Ascherio","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ana.1052","article-title":"Prospective study of caffeine consumption and risk of Parkinson's disease in men and women","volume":"50","author":"Ascherio","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1212\/01.WNL.0000046523.05125.87","article-title":"Caffeine, postmenopausal estrogen, and risk of Parkinson's disease","volume":"60","author":"Ascherio","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib416","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/aje\/kwh312","article-title":"Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen","volume":"160","author":"Ascherio","year":"2004","journal-title":"Amer J Epidem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s007020300001","article-title":"Sleep disturbances in Parkinsonism","volume":"110","author":"Askenasy","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0169-328X(94)90048-5","article-title":"Adenosine A2A receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study","volume":"22","author":"Augood","year":"1994","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1353-8020(96)00047-8","article-title":"Premorbid dietetic habits and risk for Parkinson's disease","volume":"3","author":"Ayuso-Peralta","year":"1997","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0006-8993(02)02536-2","article-title":"Quantitative autoradiography of adenosine receptors and NBTI-sensitive adenosine transporters in the brains and spinal cords of mice deficient in the mu-opioid receptor gene","volume":"943","author":"Bailey","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib17","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/00000542-200206000-00025","article-title":"Role of adenosine receptors in spinal G-protein activation after peripheral nerve injury","volume":"96","author":"Bantel","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A(2A) receptor antagonist treatment of Parkinson's disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0304-3940(02)00524-4","article-title":"Effects of A(1) and A(2A) adenosine receptor ligands in mouse acute models of pain","volume":"328","author":"Bastia","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib21","article-title":"A crucial role for forebrain adenosine A2A receptors in amphetamine sensitization","author":"Bastia","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib22","first-page":"1066","article-title":"The A2A adenosine receptor mediates coronary vasodilation","volume":"284","author":"Belardinelli","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.brainres.2004.02.039","article-title":"Caffeinol confers cortical but not subcortical neuroprotection after transient focal cerebral ischemia in rats","volume":"1008","author":"Belayev","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00000539-199510000-00010","article-title":"Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain","volume":"81","author":"Belfrage","year":"1995","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00000539-199907000-00023","article-title":"The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain","volume":"89","author":"Belfrage","year":"1999","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib26","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/WNL.55.9.1350","article-title":"Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study","volume":"55","author":"Benedetti","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib27","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/0009-9236(95)90025-X","article-title":"Sympathomimetic effects of paraxanthine and caffeine in humans","volume":"58","author":"Benowitz","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmthera.2004.10.007_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease","volume":"184","author":"Bibbiani","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib29","first-page":"818","article-title":"Striatal acetylcholine release correlates with behavioral sensitizatoin in rats withdrawn from chronic amphetamine","volume":"282","author":"Bickerdike","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0301-0082(99)00067-2","article-title":"Functional changes of the basal ganglia circuitry in Parkinson's disease","volume":"62","author":"Blandini","year":"2000","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/(SICI)1098-2396(199601)22:1<70::AID-SYN8>3.0.CO;2-F","article-title":"Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol","volume":"22","author":"Boegman","year":"1996","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-2999(90)90643-K","article-title":"Adenosine A2 stimulation of tyrosine hydroxylase in rat striatal minces is reversed by dopamine D2 autoreceptor activation","volume":"185","author":"Booth","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/brain\/124.3.546","article-title":"Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey","volume":"124","author":"Boraud","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/syn.10112","article-title":"Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats","volume":"46","author":"Bove","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/glia.10243","article-title":"Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes","volume":"43","author":"Brambilla","year":"2003","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0014-5793(98)00556-0","article-title":"Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells","volume":"429","author":"Brodie","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib38","first-page":"S105","article-title":"The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease","volume":"47","author":"Brotchie","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib39","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1189\/jlb.72.5.1027","article-title":"The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells","volume":"72","author":"Bshesh","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib40","first-page":"S60","article-title":"Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?","volume":"47","author":"Calabresi","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib42","first-page":"S70","article-title":"Molecular basis of levodopa-induced dyskinesias","volume":"47","author":"Calon","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib43","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awh128","article-title":"Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias","volume":"127","author":"Calon","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib44","first-page":"S53","article-title":"Patterns of gene expression and behavior induced by chronic dopamine treatments","volume":"47","author":"Canales","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib45","doi-asserted-by":"crossref","first-page":"46741","DOI":"10.1074\/jbc.M306451200","article-title":"Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer","volume":"278","author":"Canals","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/syn.10066","article-title":"Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent l-dopa and A2A receptor blockade plus l-dopa in dopamine-denervated rats","volume":"44","author":"Carta","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib47","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1023\/A:1007644128886","article-title":"Regulation of AMPA receptors by phosphorylation","volume":"25","author":"Carvalho","year":"2000","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1067\/mva.2001.117996","article-title":"An adenosine A2A agonist, ATL-146e, reduces paralysis and apoptosis during rabbit spinal cord reperfusion","volume":"34","author":"Cassada","year":"2001","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0006-8993(94)90327-1","article-title":"Presynaptic adenosine A2A receptors on soma and central terminals of rat vagal afferent neurons","volume":"652","author":"Castillo-Melendez","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib50","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib52","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/jnnp.65.5.781","article-title":"Genetic and environmental risk factors for Parkinson's disease in a Chinese population","volume":"65","author":"Chan","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 5","key":"10.1016\/j.pharmthera.2004.10.007_bib53","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.50.5_Suppl_5.S17","article-title":"Levodopa therapy: consequences of the nonphysiologic replacement of dopamine","volume":"50","author":"Chase","year":"1998","journal-title":"Neurology"},{"issue":"11 Suppl 6","key":"10.1016\/j.pharmthera.2004.10.007_bib54","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1212\/01.WNL.0000095223.08711.48","article-title":"Translating A2A antagonist KW6002 from animal models to parkinsonian patients","volume":"61","author":"Chase","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/aje\/155.8.732","article-title":"Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake","volume":"155","author":"Checkoway","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib56","first-page":"824.11","article-title":"Deficiency of the A2A adenosine receptor attenuates striatal dopamine release as well as spontaneous and amphetamine-induced locomotion","volume":"24","author":"Chen","year":"1998","journal-title":"Abstr - Soc Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib57","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1523\/JNEUROSCI.19-21-09192.1999","article-title":"A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice","volume":"19","author":"Chen","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib59","unstructured":"Chen, J. F., Staal, R., Xu, K., Beilstein, M., Sonsalla, P. K., & Schwarzschild, M. A. (2000). Novel neuroprotection by adenosine A2A receptor inactivation in an MPTP model of Parkinson's disease. Move Dis 15 (Suppl 3), S37, P304."},{"key":"10.1016\/j.pharmthera.2004.10.007_bib60","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1073\/pnas.98.4.1970","article-title":"The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice","volume":"98","author":"Chen","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib61","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease","volume":"21","author":"Chen","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib62","doi-asserted-by":"crossref","first-page":"36040","DOI":"10.1074\/jbc.M206830200","article-title":"8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism","volume":"277","author":"Chen","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib63","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/sj.npp.1300152","article-title":"Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization","volume":"28","author":"Chen","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"11 Suppl 6","key":"10.1016\/j.pharmthera.2004.10.007_bib64","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1212\/01.WNL.0000095218.26363.7B","article-title":"Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease","volume":"61","author":"Chen","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib65","doi-asserted-by":"crossref","first-page":"33930","DOI":"10.1074\/jbc.M201206200","article-title":"Essential role of cAMP-response element-binding protein activation by A2A adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade","volume":"277","author":"Cheng","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib66","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0006-291X(05)90000-4","article-title":"Molecular cloning of a novel adenosine receptor gene from rat brain","volume":"185","author":"Chern","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib68","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nn0901-873","article-title":"Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice","volume":"4","author":"Chiamulera","year":"2001","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0006-8993(97)00445-9","article-title":"2-Phenylaminoadenosine stimulates dopamine synthesis in rat forebrain in vitro and in vivo via adenosine A2 receptors","volume":"761","author":"Choksi","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib70","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.npp.1300444","article-title":"Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats","volume":"29","author":"Coccurello","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0166-4328(03)00178-5","article-title":"The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism","volume":"148","author":"Correa","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib72","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00001756-199903170-00005","article-title":"Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats","volume":"10","author":"Corsi","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib73","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1097\/00001756-200008030-00048","article-title":"Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats","volume":"11","author":"Corsi","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01352-9","article-title":"Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats","volume":"464","author":"Corsi","year":"2003","journal-title":"Eur J Pharm"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib75","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1046\/j.1471-4159.2001.00201.x","article-title":"Galpha(olf) is necessary for coupling D1 and A2A receptors to adenylyl cyclase in the striatum","volume":"76","author":"Corvol","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3940(00)01295-7","article-title":"Adenosine A2A receptor facilitation of synaptic transmission in the CA1 area of the rat hippocampus requires protein kinase C but not protein kinase A activation","volume":"289","author":"Cunha","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib77","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0006-8993(94)91066-9","article-title":"Evidence for functionally important adenosine A2A receptors in the rat hippocampus","volume":"649","author":"Cunha","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00168627","article-title":"Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors","volume":"353","author":"Cunha","year":"1996","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib79","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/PL00005355","article-title":"G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors","volume":"359","author":"Cunha","year":"1999","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib80","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0306-4522(01)00372-4","article-title":"Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission","volume":"107","author":"D'Alcantara","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib81","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.bjp.0705185","article-title":"Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity","volume":"138","author":"Dall'Igna","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00734999","article-title":"Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines","volume":"3","author":"Daly","year":"1983","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib83","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(96)00665-6","article-title":"Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells","volume":"316","author":"Dasgupta","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/syn.1100","article-title":"Acute and chronic caffeine administration differentially alters striatal gene expression in wild-type and adenosine A(2A) receptor-deficient mice","volume":"42","author":"Dassesse","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib85","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1471-4159.2001.00389.x","article-title":"Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors","volume":"78","author":"Dassesse","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib86","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1087753","article-title":"Molecular pathways of neurodegeneration in Parkinson's disease","volume":"302","author":"Dawson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib87","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00210-002-0613-3","article-title":"Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385","volume":"366","author":"DeMet","year":"2002","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib88","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1097\/00001756-200107030-00014","article-title":"Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum","volume":"12","author":"Diaz-Cabiale","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib89","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0304-3940(02)00179-9","article-title":"Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors","volume":"324","author":"Diaz-Cabiale","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib90","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1476-5381.1996.tb15561.x","article-title":"Tissue distribution of adenosine receptor mRNAs in the rat","volume":"118","author":"Dixon","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib91","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/00000542-200210000-00028","article-title":"Dose response of intrathecal adenosine in experimental pain and allodynia","volume":"97","author":"Eisenach","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000542-200201000-00011","article-title":"Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans","volume":"96","author":"Eisenach","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib93","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1399-6576.1995.tb04158.x","article-title":"Adenosine increases the cutaneous heat pain threshold in healthy volunteers","volume":"39","author":"Ekblom","year":"1995","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib94","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.neuroscience.2003.10.043","article-title":"Stimulation of adenosine A2A receptors elicits zif\/268 and NMDA epsilon2 subunit mRNA expression in cortex and striatum of the \u201cweaver\u201d mutant mouse, a genetic model of nigrostriatal dopamine deficiency","volume":"123","author":"Ekonomou","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib95","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00005053-196704000-00005","article-title":"Amphetamine psychosis: I. Desperation of the individual and process","volume":"144","author":"Ellinwood","year":"1967","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib96","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjp.0703170","article-title":"The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors","volume":"129","author":"El Yacoubi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib97","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-2999(00)00399-X","article-title":"SCH 58261 and ZM 241385 differentially prevent the motor effects of CGS 21680 in mice: evidence for a functional \u2018atypical\u2019 adenosine A(2A) receptor","volume":"401","author":"El Yacoubi","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjp.0704240","article-title":"Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice","volume":"134","author":"El Yacoubi","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib99","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/00001756-200104170-00024","article-title":"Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy","volume":"12","author":"El Yacoubi","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib100","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1212\/01.WNL.0000095220.87550.F6","article-title":"Adenosine A2A receptors and depression","volume":"61","author":"El Yacoubi","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib101","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/1531-8257(199901)14:1<28::AID-MDS1007>3.0.CO;2-O","article-title":"Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden","volume":"14","author":"Fall","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib102","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/WNL.61.3.286","article-title":"Nondopaminergic symptomatic therapies for Parkinson's disease: turn on or turn off?","volume":"61","author":"Feigin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(96)00944-2","article-title":"Adenosine A2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats","volume":"321","author":"Fenu","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib104","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s002130050380","article-title":"Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia","volume":"133","author":"Ferr\u00e9","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0006-8993(92)91036-E","article-title":"Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum","volume":"594","author":"Ferr\u00e9","year":"1992","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib414","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.88.16.7238","article-title":"Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes","volume":"88","author":"Ferr\u00e9","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib106","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1523\/JNEUROSCI.13-12-05402.1993","article-title":"The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain","volume":"13","author":"Ferr\u00e9","year":"1993","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib107","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0922-4106(93)90157-5","article-title":"Opposing actions of an adenosine A2 receptor agonist and a GTP analogue on the regulation of dopamine D2 receptors in rat neostriatal membranes","volume":"244","author":"Ferr\u00e9","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib108","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0306-4522(94)90521-5","article-title":"Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia","volume":"63","author":"Ferr\u00e9","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib109","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02245329","article-title":"Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum","volume":"116","author":"Ferr\u00e9","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib110","doi-asserted-by":"crossref","first-page":"11940","DOI":"10.1073\/pnas.172393799","article-title":"Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function","volume":"99","author":"Ferr\u00e9","year":"2002","journal-title":"Proc Nat Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib111","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2","article-title":"Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2A-receptors","volume":"18","author":"Fiebich","year":"1996","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib112","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0169-328X(92)90173-9","article-title":"Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum","volume":"14","author":"Fink","year":"1992","journal-title":"Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib113","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.1471-4159.2003.02145.x","article-title":"Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage","volume":"88","author":"Fink","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib114","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(02)01305-5","article-title":"Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat","volume":"438","author":"Fozard","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib115","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1523\/JNEUROSCI.22-03-01054.2002","article-title":"Persistent behavioral sensitization to chronic l-DOPA requires A2A adenosine receptors","volume":"22","author":"Fredduzzi","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib116","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1046\/j.1471-4159.1998.70031210.x","article-title":"[3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies","volume":"70","author":"Fredholm","year":"1998","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib117","first-page":"83","article-title":"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use","volume":"51","author":"Fredholm","year":"1999","journal-title":"Pharm Rev"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib118","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s002100000313","article-title":"Structure and function of adenosine receptors and their genes","volume":"362","author":"Fredholm","year":"2000","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib119","first-page":"527","article-title":"International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharm Rev"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0169-328X(92)90152-2","article-title":"Molecular characterization of a human brain adenosine A2 receptor","volume":"15","author":"Furlong","year":"1992","journal-title":"Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib121","first-page":"48","article-title":"Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists","volume":"52","author":"Fuxe","year":"1974","journal-title":"Med Biol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib122","first-page":"345","article-title":"Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum","volume":"86","author":"Fuxe","year":"2001","journal-title":"Adv Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib123","doi-asserted-by":"crossref","first-page":"PL61","DOI":"10.1016\/0024-3205(94)00889-2","article-title":"CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil","volume":"55","author":"Gao","year":"1994","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib124","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1523\/JNEUROSCI.14-10-06084.1994","article-title":"Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain","volume":"14","author":"Garris","year":"1994","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-2999(02)02301-4","article-title":"Adenosine A2A receptors inhibit the N-methyl-d-aspartate component of excitatory synaptic currents in rat striatal neurons","volume":"451","author":"Gerevich","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib126","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib127","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/BF01291788","article-title":"Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man","volume":"103","author":"Gerlach","year":"1996","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0006-8993(03)02942-1","article-title":"Adenosine A(2A) antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease","volume":"979","author":"Gianfriddo","year":"2003","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib131","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.870010106","article-title":"Pain in Parkinson's disease","volume":"1","author":"Goetz","year":"1986","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib132","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.neuropharm.2004.04.018","article-title":"Striatal adenosine A2A receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats","volume":"47","author":"Golembiowska","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib133","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0006-8993(98)00743-4","article-title":"Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum","volume":"806","author":"Golembiowska","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib134","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3940(97)00803-3","article-title":"Adenosine A2A receptors facilitate 45Ca2+ uptake through class A calcium channels in rat hippocampal CA3 but not CA1 synaptosomes","volume":"238","author":"Goncalves","year":"1997","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib135","first-page":"239","article-title":"Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease","volume":"20","author":"Gorell","year":"1999","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib136","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/oxfordjournals.aje.a116960","article-title":"Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease","volume":"139","author":"Grandinetti","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib137","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00002826-200103000-00001","article-title":"Glutamatergic influences on the basal ganglia","volume":"24","author":"Greenamyre","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib138","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib417","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1046\/j.1471-4159.2003.01600.x","article-title":"Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice","volume":"84","author":"Gross","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib139","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1471-4159.1996.67010374.x","article-title":"Dual signalling by the adenosine A2A receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals","volume":"67","author":"Gubitz","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0014-2999(00)00682-8","article-title":"Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist","volume":"406","author":"Halldner","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib141","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.neuropharm.2004.01.014","article-title":"The adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion: a study in mice lacking adenosine A1 and\/or A2A receptors","volume":"46","author":"Halldner","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib142","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000065418","article-title":"The association between disease severity and sleep-related problems in patients with Parkinson's disease","volume":"46","author":"Happe","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib143","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/00001756-199704140-00038","article-title":"Adenosine A2A receptors in the nucleus accumbens modulate prepulse inhibition of the startle response","volume":"8","author":"Hauber","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib144","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1097\/00001756-199806010-00024","article-title":"Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen","volume":"9","author":"Hauber","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib145","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1046\/j.0953-816x.2001.01759.x","article-title":"Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats","volume":"14","author":"Hauber","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib146","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib147","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00442002","article-title":"Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice","volume":"98","author":"Heffner","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib148","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/(SICI)1098-2396(199610)24:2<182::AID-SYN10>3.0.CO;2-0","article-title":"Evidence for an involvement of muscarinic cholinergic systems in the induction but not expression of behavioral sensitization to cocaine","volume":"2","author":"Heidbreder","year":"1996","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib149","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1212\/WNL.47.3.636","article-title":"Diet and Parkinson's disease: I. A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study","volume":"47","author":"Hellenbrand","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","article-title":"Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"151","author":"Henry","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib418","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/exnr.1998.6996","article-title":"Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat","volume":"155","author":"Henry","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib151","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","article-title":"Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"171","author":"Henry","year":"2001","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib424","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0306-4522(95)00120-8","article-title":"Effects of l-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum","volume":"68","author":"Herrero","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib152","first-page":"2056","article-title":"Adenosine A2A receptors in rat striatum: prevalent dendritic localization post-synaptic to catecholaminergic terminals","volume":"24","author":"Hettinger","year":"1998","journal-title":"Abstr - Soc Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib153","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W","article-title":"Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum","volume":"431","author":"Hettinger","year":"2001","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib154","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1074\/jbc.M107731200","article-title":"Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors","volume":"277","author":"Hillion","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib155","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1212\/WNL.39.10.1314","article-title":"Epidemiologic study of Parkinson's disease in Hong Kong","volume":"39","author":"Ho","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib156","first-page":"62","article-title":"Role of adenosine receptors in caffeine tolerance","volume":"256","author":"Holtzman","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib157","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.expneurol.2004.05.008","article-title":"Lost in translation: taking neuroprotection from animal models to clinical trials","volume":"188","author":"Hoyte","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib158","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.0022-3042.2001.00694.x","article-title":"Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease","volume":"80","author":"Ikeda","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib159","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14728222.4.5.635","article-title":"Adenosine receptor in neurological disorders","volume":"4","author":"Impagnatiello","year":"2000","journal-title":"Emerg Ther Targets"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib428","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0014-5793(93)81466-D","article-title":"8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo","volume":"323","author":"Jacobson","year":"1993","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib160","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1476-5381.1992.tb14240.x","article-title":"Adenosine receptors in post-mortem human brain","volume":"105","author":"James","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib161","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-2999(89)90571-2","article-title":"Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680","volume":"168","author":"Jarvis","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib162","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/01.WNL.0000095209.59347.79","article-title":"A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib163","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1212\/WNL.62.1_suppl_1.S47","article-title":"Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation","volume":"62","author":"Jenner","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib164","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/mds.870070407","article-title":"Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control study","volume":"7","author":"Jimenez-Jimenez","year":"1992","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/PL00004917","article-title":"Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release","volume":"355","author":"Jin","year":"1997","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib166","first-page":"801","article-title":"Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices","volume":"267","author":"Jin","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib167","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.parkreldis.2004.06.004","article-title":"Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence","volume":"10","author":"Joghataie","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib168","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0028-3908(95)00009-U","article-title":"Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiography","volume":"34","author":"Johansson","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib169","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0922-4106(93)90066-I","article-title":"The binding of the adenosine A2 receptor selective agonist [3H]CGS 21680 to rat cortex differs from its binding to rat striatum","volume":"247","author":"Johansson","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib170","doi-asserted-by":"crossref","first-page":"9407","DOI":"10.1073\/pnas.161292398","article-title":"Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor","volume":"98","author":"Johansson","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib171","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.1329209","article-title":"Burst firing in dopamine neurons induced by N-methyl-d-aspartate: role of electrogenic sodium pump","volume":"258","author":"Johnson","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib423","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0169-328X(95)00084-6","article-title":"l-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP","volume":"32","author":"Jolkkonen","year":"1995","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib172","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0306-4522(97)00613-1","article-title":"Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists","volume":"85","author":"Jones","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib173","unstructured":"Kachroo, A., Grandy, D. K., Chen, J.-F., Orlando, L., & Schwarzschild, M. A. (2004). Metabotropic glutamate 5 (mGlu5) receptor antagonist-induced locomotion requires adenosine A2A and dopamine D2 receptors and is potentiated by an A2A antagonist. Mov Disord 19 (S9), S390, P1141."},{"key":"10.1016\/j.pharmthera.2004.10.007_bib174","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3940(98)00216-X","article-title":"Expression of adenosine A2A receptor gene in rat dorsal root and autonomic ganglia","volume":"246","author":"Kaelin-Lang","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0304-3940(99)00022-1","article-title":"Expression of adenosine A2A receptors gene in the olfactory bulb and spinal cord of rat and mouse","volume":"261","author":"Kaelin-Lang","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib176","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s007020070037","article-title":"Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion","volume":"107","author":"Kaelin-Lang","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib177","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(95)00668-0","article-title":"Selective adenosine A2A receptor\/dopamine D2 receptor interactions in animal models of schizophrenia","volume":"295","author":"Kafka","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib178","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/syn.890050104","article-title":"The effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens","volume":"5","author":"Kalivas","year":"1990","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib179","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0006-291X(03)00991-4","article-title":"Oligomerization of adenosine A2A and dopamine D2 receptors in living cells","volume":"306","author":"Kamiya","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0014-2999(94)90551-7","article-title":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity","volume":"256","author":"Kanda","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib181","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib182","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/exnr.2000.7350","article-title":"Combined use of the adenosine A(2A) antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys","volume":"162","author":"Kanda","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib183","first-page":"1563","article-title":"Caffeine treatment and withdrawal in mice: relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding","volume":"266","author":"Kaplan","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib184","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/j.1552-4604.1997.tb04356.x","article-title":"Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans","volume":"37","author":"Kaplan","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib185","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0006-8993(96)00248-X","article-title":"A novel nicotinic-cholinergic role in behavioral sensitization to amphetamine-induced stereotypy in mice","volume":"725","author":"Karler","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib186","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00000539-199504000-00037","article-title":"An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection","volume":"80","author":"Karlsten","year":"1995","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib187","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1212\/WNL.26.8.741","article-title":"Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism","volume":"26","author":"Kartzinel","year":"1976","journal-title":"Neurology"},{"issue":"11 Suppl 6","key":"10.1016\/j.pharmthera.2004.10.007_bib188","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/01.WNL.0000095219.22086.31","article-title":"Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease","volume":"61","author":"Kase","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib189","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neulet.2003.10.040","article-title":"Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors","volume":"355","author":"Kaster","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(95)00479-3","article-title":"Adenosine A2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation","volume":"287","author":"Kearney","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib191","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1073\/pnas.252753799","article-title":"Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice","volume":"100","author":"Kim","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib192","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1046\/j.1471-4159.1994.62030960.x","article-title":"Adenosine A2A receptor-mediated modulation of striatal [3H]GABA and [3H]acetylcholine release","volume":"62","author":"Kirk","year":"1994","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib193","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1995.tb13260.x","article-title":"Further characterization of [3H]-CGS 21680 binding sites in the rat striatum and cortex","volume":"114","author":"Kirk","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib194","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1476-5381.1993.tb13905.x","article-title":"Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes","volume":"110","author":"Kirkpatrick","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib429","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00005131","article-title":"Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells","volume":"357","author":"Klotz","year":"1998","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib195","first-page":"668","article-title":"KW-6002 (Kyowa Hakko Kogyo)","volume":"2","author":"Knutsen","year":"2001","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib196","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(00)00745-7","article-title":"Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats","volume":"408","author":"Koga","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib197","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1023\/A:1012380416876","article-title":"Modulation of ionotropic glutamate receptor channels","volume":"26","author":"Koles","year":"2001","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib198","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1212\/WNL.34.7.957","article-title":"Sensory symptoms in Parkinson's disease","volume":"34","author":"Koller","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib199","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/WNL.52.9.1916","article-title":"Theophylline increases \u201con\u201d time in advanced parkinsonian patients","volume":"52","author":"Kostic","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib200","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0091-3057(98)00236-6","article-title":"Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice","volume":"63","author":"Kowaluk","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib201","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00002826-200201000-00005","article-title":"A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease","volume":"25","author":"Kulisevsky","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib202","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0006-2952(99)00184-7","article-title":"Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors","volume":"58","author":"Kull","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib203","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/mol.58.4.771","article-title":"Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum","volume":"58","author":"Kull","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib204","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1476-5381.1994.tb16171.x","article-title":"Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release","volume":"113","author":"Kurokawa","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib205","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1471-4159.1996.66051882.x","article-title":"Adenosine A2A receptor-mediated modulation of striatal acetylcholine release in vivo","volume":"66","author":"Kurokawa","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib206","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib207","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.expneurol.2004.03.003","article-title":"Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence","volume":"188","author":"Lapchak","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib208","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1523\/JNEUROSCI.17-20-08038.1997","article-title":"Dopamine-adenosine interactions in the striatum and the globus pallidus: inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor-mediated effects on c-fos expression","volume":"17","author":"Le Moine","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib209","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/41771","article-title":"Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor","volume":"388","author":"Ledent","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib210","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1046\/j.1460-9568.2003.02907.x","article-title":"Characterization of the rat A2A adenosine receptor gene: a 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system","volume":"18","author":"Lee","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib211","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mds.10387","article-title":"Higher incidence of depression preceding the onset of Parkinson's disease: a register study","volume":"18","author":"Leentjens","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib212","unstructured":"LeWitt, P. A., & the 6002-US-005\/US-006 Clinical Investigator Group (2004). \u201cOff\u201d time reduction from adjunctive use of istradefylline (KW-6002) in levodopa-treated patients with advanced Parkinson's disease. Move Disord 19 (S9) S222, P624."},{"key":"10.1016\/j.pharmthera.2004.10.007_bib213","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0024-3205(00)01036-5","article-title":"Adenosine enhances glial glutamate efflux via A2A adenosine receptors","volume":"68","author":"Li","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib214","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.2541503","article-title":"Selective amplification and cloning of four new members of the G protein-coupled receptor family","volume":"244","author":"Libert","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib430","first-page":"705","article-title":"Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells","volume":"56","author":"Linden","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib215","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nature00817","article-title":"Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine","volume":"418","author":"Lindskog","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib216","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1212\/WNL.48.6.1583","article-title":"Environmental risk factors and Parkinson's disease: a case-control study in Taiwan","volume":"48","author":"Liou","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib217","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/sj.bjp.0705692","article-title":"Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice","volume":"141","author":"Lopes","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib218","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/phrs.1996.0120","article-title":"Cardioprotective effects of adenosine A1 and A2A receptor agonists in the isolated rat heart","volume":"35","author":"Lozza","year":"1997","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib219","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib220","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib221","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1074549","article-title":"Subthalamic GAD gene therapy in a Parkinson's disease rat model","volume":"298","author":"Luo","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib222","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1006\/geno.1994.1181","article-title":"Mapping of a human A2A adenosine receptor (ADORA2) to chromosome 22","volume":"20","author":"MacCollin","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib223","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0006-291X(05)80909-X","article-title":"RDC8 codes for an adenosine A2 receptor with physiological constitutive activity","volume":"173","author":"Maenhaut","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib224","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3171\/jns.2004.100.4.0679","article-title":"Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons","volume":"100","author":"Maesawa","year":"2004","journal-title":"J Neurosurg"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib225","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.2042-7158.1994.tb03840.x","article-title":"The effect of theophylline on parkinsonian symptoms","volume":"46","author":"Mally","year":"1994","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib226","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00000542-199308000-00012","article-title":"Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and l-PIA on the formalin test and an isobolographic analysis of the NSAID interaction","volume":"79","author":"Malmberg","year":"1993","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib227","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/sj.bjp.0704712","article-title":"Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes","volume":"136","author":"Marchi","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib228","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0028-3908(03)00156-4","article-title":"Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices","volume":"45","author":"Marcoli","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib229","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0306-4522(02)00561-4","article-title":"Enhancement of rapid eye movement sleep in the rat by actions at A1 and A2A adenosine receptor subtypes with a differential sensitivity to atropine","volume":"116","author":"Marks","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib230","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/jnnp.50.1.105","article-title":"Parkinson's disease in twins","volume":"50","author":"Marsden","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib231","first-page":"1023","article-title":"Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques","volume":"285","author":"Marston","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib232","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0306-4522(91)90038-P","article-title":"Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease","volume":"42","author":"Martinez-Mir","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib233","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1212\/WNL.38.8.1217","article-title":"Parkinson's disease in a nationwide twin cohort","volume":"38","author":"Marttila","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib234","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/j.1471-4159.1993.tb03526.x","article-title":"Adenosine A2A receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus","volume":"60","author":"Mayfield","year":"1993","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib235","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/(SICI)1098-2396(199602)22:2<132::AID-SYN6>3.0.CO;2-E","article-title":"Opposing actions of adenosine A2A and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2A\/D2 receptor interaction in globus pallidus","volume":"22","author":"Mayfield","year":"1996","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib236","first-page":"D1","article-title":"The caffeine count in your morning fix","author":"McCarthy","year":"2004","journal-title":"Wall Street J"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib237","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0006-3223(03)00530-4","article-title":"Prevalence, etiology, and treatment of depression in Parkinson's disease","volume":"54","author":"McDonald","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib238","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-8993(02)03753-8","article-title":"The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat","volume":"959","author":"Melani","year":"2003","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib239","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF00971338","article-title":"Cloning and expression of the A2A adenosine receptor from guinea pig brain","volume":"19","author":"Meng","year":"1994","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib240","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1073\/pnas.060496197","article-title":"Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human","volume":"97","author":"Mezey","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib241","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1097\/00001756-199812010-00034","article-title":"Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats","volume":"9","author":"Monopoli","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib242","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","article-title":"Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib243","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.neulet.2004.06.022","article-title":"Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exporatory activity in reserpinized rats","volume":"367","author":"Moo-Puc","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib244","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1600-0404.1994.tb01655.x","article-title":"Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain","volume":"89","author":"Morano","year":"1994","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib413","first-page":"161.1","article-title":"Localization of adenosine A2A receptor mRNA in neurochemically identified striatal neurons in the human compared to the rat","volume":"24","author":"Moratalla","year":"1998","journal-title":"Soc Neurosci Abstr"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-2999(94)90438-3","article-title":"Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats","volume":"251","author":"Morelli","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib246","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0306-4522(94)00602-2","article-title":"Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats","volume":"67","author":"Morelli","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib247","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.45.6.1041","article-title":"Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?","volume":"45","author":"Morens","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib248","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0273-2300(82)90003-4","article-title":"Amount and dietary sources of caffeine and saccharin intake by individuals ages 5 to 18 years","volume":"2","author":"Morgan","year":"1982","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib249","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/01.WNL.0000095211.71092.A0","article-title":"Modulation of GABAergic transmission in the striatopallidal system by adenosine A(2A) receptors: a potential mechanism for the antiparkinsonian effects of A(2A) antagonists","volume":"61","author":"Mori","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib250","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1523\/JNEUROSCI.16-02-00605.1996","article-title":"The role of adenosine A2A receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons","volume":"16","author":"Mori","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib251","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-328X(97)00123-X","article-title":"Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy","volume":"49","author":"Morissette","year":"1997","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib252","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/syn.10240","article-title":"Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats","volume":"49","author":"Nagel","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib253","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-8993(89)90647-1","article-title":"Adenosinergic modulation of caffeine-induced c-fos mRNA expression in mouse brain","volume":"501","author":"Nakajima","year":"1989","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib254","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1523\/JNEUROSCI.20-20-07782.2000","article-title":"A common signaling pathway for striatal NMDA and adenosine A2A receptors: implications for the treatment of Parkinson's disease","volume":"20","author":"Nash","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib255","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/syn.10234","article-title":"Dual effects of intermittent or continuous l-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion","volume":"49","author":"Nielsen","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib256","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1073\/pnas.0237126100","article-title":"Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling","volume":"100","author":"Nishi","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib257","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/glia.10100","article-title":"A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors","volume":"39","author":"Nishizaki","year":"2002","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib258","first-page":"817","article-title":"Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes","volume":"46","author":"Nonaka","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib259","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/sj.bjp.0701347","article-title":"Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones","volume":"122","author":"Norenberg","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib260","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF01345239","article-title":"Adenosine A2A receptors inhibit the conductance of NMDA receptor channels in rat neostriatal neurons","volume":"14","author":"Norenberg","year":"1998","journal-title":"Amino Acids"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib261","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4522(00)00250-5","article-title":"Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study","volume":"100","author":"Ochi","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib262","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuroscience.2004.04.050","article-title":"Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease","volume":"127","author":"Ochi","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib263","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1389-9457(01)00127-7","article-title":"The prevalence of sleep disorders in patients with Parkinson's disease. A self-reported, community-based survey","volume":"3","author":"Oerlemans","year":"2002","journal-title":"Sleep Med"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib264","doi-asserted-by":"crossref","first-page":"15175","DOI":"10.1074\/jbc.270.25.15175","article-title":"G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C","volume":"270","author":"Offermanns","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(97)00355-8","article-title":"Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat","volume":"228","author":"Oh","year":"1997","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib266","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0006-8993(99)01121-X","article-title":"Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits","volume":"821","author":"Oh","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib267","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/BF02245625","article-title":"Scopalamine prevents the development of sensitization to methamphetamine","volume":"121","author":"Ohmori","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib268","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/414916a","article-title":"Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage","volume":"414","author":"Ohta","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib269","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3940(96)12780-4","article-title":"Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum","volume":"212","author":"Okada","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib271","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0014-2999(98)00730-4","article-title":"Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in vitro","volume":"362","author":"O'Kane","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib272","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2002.282.1.F10","article-title":"A(2A) adenosine receptor: a novel therapeutic target in renal disease","volume":"282","author":"Okusa","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib273","doi-asserted-by":"crossref","first-page":"F809","DOI":"10.1152\/ajprenal.2000.279.5.F809","article-title":"A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion","volume":"279","author":"Okusa","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib431","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pa.35.040195.003053","article-title":"Adenosine receptor subtypes: characterization and therapeutic regulation","volume":"35","author":"Olah","year":"1995","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib274","first-page":"S167","article-title":"Preventing levodopa-induced dyskinesias","volume":"47","author":"Olanow","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib275","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0006-8993(88)90232-6","article-title":"Evidence that adenosine A2 and dopamine autoreceptors antagonistically regulate tyrosine hydroxylase activity in rat striatal synaptosomes","volume":"456","author":"Onali","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib432","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/PL00005326","article-title":"Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors","volume":"359","author":"Ongini","year":"1999","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib276","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0304-3940(92)90498-V","article-title":"The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex","volume":"138","author":"O'Regan","year":"1992","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib277","series-title":"Program No. 487.6. 2002 Abstract viewer\/itinerary planner","article-title":"Caffeine attenuates MPTP-induced loss of dopaminergic neurons in substantia nigra in mice","author":"Oztas","year":"2002"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib279","series-title":"An essay on the shaking palsy","author":"Parkinson","year":"1817"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib278","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00178977","article-title":"Autoradiographic evidence for G-protein coupled A2-receptors in rat neostriatum using [3H]-CGS 21680 as a ligand","volume":"342","author":"Parkinson","year":"1990","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib280","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1046\/j.1471-4159.1995.65052057.x","article-title":"Neuroleptics up-regulate adenosine A2A receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia","volume":"65","author":"Parsons","year":"1995","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib282","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1523\/JNEUROSCI.12-10-03729.1992","article-title":"D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease","volume":"12","author":"Paul","year":"1992","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib281","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0014-4886(03)00363-7","article-title":"Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease","volume":"185","author":"Paul","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib419","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1046\/j.1460-9568.2002.02275.x","article-title":"AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with l-dopa","volume":"16","author":"Perier","year":"2002","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib420","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1046\/j.1471-4159.2003.01960.x","article-title":"Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats","volume":"86","author":"Perier","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib283","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1471-4159.1996.66010362.x","article-title":"Characterization and expression of the human A2A adenosine receptor gene","volume":"66","author":"Peterfreund","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib284","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0968-0896(02)00648-X","article-title":"Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists","volume":"11","author":"Petzer","year":"2003","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib285","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0006-8993(95)01153-6","article-title":"The effects of selective A1 and A2A adenosine receptor antagonists on cerebral ischemic injury in the gerbil","volume":"705","author":"Phillis","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib286","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1460-9568.1996.tb01603.x","article-title":"Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies","volume":"8","author":"Piallat","year":"1996","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib287","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O","article-title":"The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins","volume":"45","author":"Piccini","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib288","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0165-0173(97)00021-0","article-title":"A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants","volume":"25","author":"Pierce","year":"1997","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib427","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2004.11.009","article-title":"KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse","author":"Pierri","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib289","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1460-9568.1996.tb01285.x","article-title":"Blockade of A2A adenosine receptors positively modulates turning behaviour and c-fos expression induced by D1 agonists in dopamine-denervated rats","volume":"8","author":"Pinna","year":"1996","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0006-8993(97)00214-X","article-title":"Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas","volume":"759","author":"Pinna","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib291","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0893-133X(98)00051-7","article-title":"Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol","volume":"20","author":"Pinna","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib292","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K","article-title":"Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats","volume":"39","author":"Pinna","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib293","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1097\/00001756-200011090-00042","article-title":"The mGlu5 receptor agonist CHPG stimulates striatal glutamate release: possible involvement of A2A receptors","volume":"11","author":"Pintor","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib294","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(01)01058-5","article-title":"SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum","volume":"421","author":"Pintor","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib295","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1471-4159.2003.02306.x","article-title":"Adenosine A2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors","volume":"89","author":"Pintor","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib296","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.STR.0000067706.23777.04","article-title":"Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke","volume":"34","author":"Piriyawat","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib297","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0306-4522(95)00168-I","article-title":"Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway","volume":"68","author":"Pollack","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib298","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0006-8993(96)01036-0","article-title":"Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-fos induction in 6-hydroxydopamine-lesioned rats","volume":"743","author":"Pollack","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib299","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0006-8993(93)91204-6","article-title":"Differential localization of A2A adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons","volume":"631","author":"Pollack","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib300","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-2999(95)00679-6","article-title":"Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats","volume":"287","author":"Popoli","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib301","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(98)00533-3","article-title":"Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats","volume":"251","author":"Popoli","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib302","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0893-133X(01)00256-1","article-title":"The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors","volume":"25","author":"Popoli","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib303","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1523\/JNEUROSCI.22-05-01967.2002","article-title":"Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum","volume":"22","author":"Popoli","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib304","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1212\/01.WNL.0000095216.89483.A2","article-title":"Modulation of glutamate release and excitotoxicity by adenosine A(2A) receptors","volume":"61","author":"Popoli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib305","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.276.5316.1265","article-title":"Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness","volume":"276","author":"Porkka-Heiskanen","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib306","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/sj.bjp.0703366","article-title":"Adenosine receptor expression and function in rat striatal cholinergic interneurons","volume":"130","author":"Preston","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib307","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000026273","article-title":"Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France","volume":"19","author":"Preux","year":"2000","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib308","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1523\/JNEUROSCI.4773-03.2004","article-title":"Direct interaction of adenosine with the TRPV1 channel protein","volume":"24","author":"Puntambekar","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib425","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0306-4522(02)00167-7","article-title":"Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not l-DOPA-induced dyskinesias in the squirrel monkey","volume":"113","author":"Quik","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib309","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000071193","article-title":"A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease","volume":"22","author":"Ragonese","year":"2003","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib310","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/00000542-199811000-00010","article-title":"Intrathecal adenosine administration: a Phase 1 clinical safety study in healthy volunteers, with additional evaluation of its influence on sensory thresholds and experimental pain","volume":"89","author":"Rane","year":"1998","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib311","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/01.WNL.0000058760.13152.1A","article-title":"Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment","volume":"60","author":"Ravina","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib312","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.1471-4159.2000.740839.x","article-title":"Correlating physiology with gene expression in striatal cholinergic neurones","volume":"74","author":"Richardson","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib313","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0893-133X(97)00033-X","article-title":"Adenosine A2A agonists: a potential new type of atypical antipsychotic","volume":"17","author":"Rimondini","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib314","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0006-8993(86)91178-9","article-title":"Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats","volume":"384","author":"Robertson","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib315","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0165-0173(86)90002-0","article-title":"Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis","volume":"396","author":"Robinson","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib316","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0006-8993(88)90549-5","article-title":"Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)amphetamine: a microdialysis study in freely moving rats","volume":"462","author":"Robinson","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib317","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF03256599","article-title":"Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease","volume":"1","author":"Rorke","year":"2002","journal-title":"Am J Respir Med"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib318","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1096-9861(19981116)401:2<163::AID-CNE2>3.0.CO;2-D","article-title":"Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system","volume":"401","author":"Rosin","year":"1998","journal-title":"J Comp Neurol"},{"issue":"Suppl. 6","key":"10.1016\/j.pharmthera.2004.10.007_bib415","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/01.WNL.0000095205.33940.99","article-title":"Anatomy of adenosine A2A receptors in brain","volume":"61","author":"Rosin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib319","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","article-title":"Association of coffee and caffeine intake with the risk of Parkinson disease","volume":"283","author":"Ross","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib320","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1471-4159.2000.0740432.x","article-title":"Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells","volume":"74","author":"Salim","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib321","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1073\/pnas.93.12.5980","article-title":"Promotion of sleep mediated by the A2A-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats","volume":"93","author":"Satoh","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib322","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-2999(98)00302-1","article-title":"Involvement of adenosine A2A receptor in sleep promotion","volume":"351","author":"Satoh","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib323","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00006676-200201000-00010","article-title":"Activation of adenosine A2A receptor pathway reduces leukocyte infiltration but enhances edema formation in rat caerulein pancreatitis","volume":"24","author":"Satoh","year":"2002","journal-title":"Pancreas"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib433","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1021\/jm9911480","article-title":"Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists","volume":"43","author":"Sauer","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib324","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0301-0082(03)00050-9","article-title":"Adenosine in the spinal cord and periphery: release and regulation of pain","volume":"69","author":"Sawynok","year":"2003","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib325","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1523\/JNEUROSCI.13-03-01080.1993","article-title":"Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons","volume":"13","author":"Schiffmann","year":"1993","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib326","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-4159.1991.tb08257.x","article-title":"Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study","volume":"57","author":"Schiffmann","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib327","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3940(91)90391-6","article-title":"Distribution of adenosine A2 receptor mRNA in the human brain","volume":"130","author":"Schiffmann","year":"1991","journal-title":"Neurosci Lett"},{"issue":"11 Suppl 6","key":"10.1016\/j.pharmthera.2004.10.007_bib328","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/01.WNL.0000095207.66853.0D","article-title":"A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission","volume":"61","author":"Schiffmann","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib329","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1017\/S0033291799003141","article-title":"What contributes to depression in Parkinson's disease?","volume":"31","author":"Schrag","year":"2001","journal-title":"Psychol Med"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib434","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0898-6568(03)00058-5","article-title":"Signalling from adenosine receptors to mitogen-activated protein kinases","volume":"15","author":"Schulte","year":"2003","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib330","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/WNL.58.10.1501","article-title":"Increased risk of Parkinson's disease after depression: a retrospective cohort study","volume":"58","author":"Schuurman","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib331","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.58.8.1154","article-title":"Caffeinated clues and the promise of adenosine A(2A) antagonists in PD","volume":"58","author":"Schwarzschild","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.pharmthera.2004.10.007_bib332","first-page":"1082","article-title":"Relating caffeine consumption to Parkinson's disease progression and dyskinesias development","volume":"18","author":"Schwarzschild","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib333","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0301-0082(95)00035-6","article-title":"Adenosine A2 receptor-mediated excitatory actions on the nervous system","volume":"48","author":"Sebastiao","year":"1996","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib334","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1213\/00000539-199410000-00029","article-title":"The influence of adenosine, ketamine, and morphine on experimentally induced ischemic pain in healthy volunteers","volume":"79","author":"Segerdahl","year":"1994","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib335","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/00000539-199506000-00013","article-title":"Preoperative adenosine infusion reduces the requirements for isoflurane and postoperative analgesics","volume":"80","author":"Segerdahl","year":"1995","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib336","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1074\/jbc.272.9.5792","article-title":"Stimulation of the mitogen-activated protein kinase via the A2A-adenosine receptor in primary human endothelial cells","volume":"272","author":"Sexl","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib435","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/S0960-894X(97)00440-X","article-title":"Adenosine A2A antagonists with potent anti-cataleptic activity","volume":"7","author":"Shimada","year":"1997","journal-title":"Bio Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib337","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(99)00899-7","article-title":"Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization","volume":"388","author":"Shimazoe","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib338","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1469-7793.2001.0423f.x","article-title":"Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus","volume":"532","author":"Shindou","year":"2001","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib339","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/sj.bjp.0704702","article-title":"Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus","volume":"136","author":"Shindou","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib340","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neulet.2003.08.059","article-title":"Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats","volume":"352","author":"Shindou","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib341","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s002130051146","article-title":"Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP","volume":"147","author":"Shiozaki","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib342","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1212\/WNL.25.8.722","article-title":"Caffeine and the antiparkinsonian response to levodopa or piribedil","volume":"25","author":"Shoulson","year":"1975","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib344","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0165-0173(00)00030-8","article-title":"Neurotrophic factors in Alzheimer's and Parkinson's disease brain","volume":"33","author":"Siegel","year":"2000","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib345","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s002130100777","article-title":"The adenosine A2A agonist CGS 21680 reverses the reduction in prepulse inhibition of the acoustic startle response induced by phencyclidine, but not by apomorphine and amphetamine","volume":"156","author":"Sills","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib346","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.expneurol.2004.05.027","article-title":"Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions","volume":"189","author":"Simola","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib347","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.22.012703.104731","article-title":"Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors","volume":"22","author":"Sitkovsky","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib348","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0304-3940(98)00092-5","article-title":"Intrathecal administration of the adenosine A1 receptor agonist R-phenylisopropyl adenosine reduces presumed pain behaviour in a rat model of central pain","volume":"243","author":"Sjolund","year":"1998","journal-title":"Neurosci Lett"},{"issue":"Pt. 4","key":"10.1016\/j.pharmthera.2004.10.007_bib349","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1469-7580.2000.19640555.x","article-title":"GABA(B) and group I metabotropic glutamate receptors in the striatopallidal complex in primates","volume":"196","author":"Smith","year":"2000","journal-title":"J Anat"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib350","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mds.10394","article-title":"Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure","volume":"18","author":"Smith","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib351","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1212\/WNL.26.5.423","article-title":"Primary sensory symptoms in parkinsonism","volume":"26","author":"Snider","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib352","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0304-3959(94)00187-J","article-title":"Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain","volume":"61","author":"Sollevi","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib353","unstructured":"Stacy, M. A., & the 60002-US-005\/US-006 Clinical Investigator Group (2004). Istradefylline (KW-6002) as adjunctive therapy in patients with advanced Parkinson's disease: a positive safety profile with supporting efficacy. Mov Disord 19 (S9), S215, P605."},{"key":"10.1016\/j.pharmthera.2004.10.007_bib354","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1152\/jn.00010.2001","article-title":"A2 adenosine receptors inhibit calcium influx through L-type calcium channels in rod photoreceptors of the salamander retina","volume":"87","author":"Stella","year":"2002","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib355","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.0962-1105.2003.00367.x","article-title":"Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor","volume":"12","author":"Stenberg","year":"2003","journal-title":"J Sleep Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib356","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ddr.1130","article-title":"Neuroprotection by A2A receptor antagonists","volume":"52","author":"Stone","year":"2001","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib357","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.2042-7158.1973.tb10012.x","article-title":"Behavioural and biochemical interaction between caffeine and l-dopa","volume":"25","author":"Stromberg","year":"1973","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib358","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1046\/j.1460-9568.2000.00288.x","article-title":"Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum","volume":"12","author":"Stromberg","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib359","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0028-3908(99)00156-2","article-title":"Combination of low dose ethanol and caffeine protects brain from damage produced by focal ischemia in rats","volume":"39","author":"Strong","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib360","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0306-4522(92)90076-E","article-title":"Relationship between dopamine release in the rat nucleus accumbens and the discharge activity of dopaminergic neurons during local in vivo application of amino acids in the ventral tegmental area","volume":"49","author":"Suaud-Chagny","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib361","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1189\/jlb.0603300","article-title":"Activation of A2A adenosine receptors inhibits expression of {alpha}4\/{beta}1 integrin (very late antigen-4) on stimulated human neutrophils","volume":"75","author":"Sullivan","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib362","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0028-3908(97)00091-9","article-title":"Caffeine mimics the effect of a dopamine D2\/3 receptor agonist on the expression of immediate early genes in globus pallidus","volume":"36","author":"Svenningsson","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib364","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1523\/JNEUROSCI.15-11-07612.1995","article-title":"Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration","volume":"15","author":"Svenningsson","year":"1995","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib365","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E","article-title":"Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study","volume":"27","author":"Svenningsson","year":"1997","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib366","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0306-4522(97)00180-2","article-title":"Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas","volume":"80","author":"Svenningsson","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib367","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0306-4522(97)00046-8","article-title":"Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens","volume":"79","author":"Svenningsson","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib368","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/(SICI)1096-9861(19980921)399:2<229::AID-CNE6>3.0.CO;2-2","article-title":"Cellular distribution of adenosine A2A receptor mRNA in the primate striatum","volume":"399","author":"Svenningsson","year":"1998","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib369","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0306-4522(97)00510-1","article-title":"Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons","volume":"84","author":"Svenningsson","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib370","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0306-4522(98)00403-5","article-title":"Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons","volume":"89","author":"Svenningsson","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib371","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0301-0082(99)00011-8","article-title":"Distribution, biochemistry and function of striatal adenosine A2A receptors","volume":"59","author":"Svenningsson","year":"1999","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib372","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1073\/pnas.97.4.1856","article-title":"Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors","volume":"97","author":"Svenningsson","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib373","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jns.2003.07.006","article-title":"Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese","volume":"216","author":"Tan","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib374","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jama.281.4.341","article-title":"Parkinson disease in twins: an etiologic study","volume":"281","author":"Tanner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib375","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/jnr.20138","article-title":"Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum","volume":"77","author":"Tebano","year":"2004","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib426","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0306-4522(02)00535-3","article-title":"Alterations in striatal neuropeptide mRNA produced by repeated administration of l-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets","volume":"115","author":"Tel","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib376","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cne.903540207","article-title":"Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons","volume":"354","author":"Testa","year":"1995","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib377","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3181\/00379727-139-36191","article-title":"Effects of caffeine and theophylline on activity of rats in relation to brain xanthine concentrations","volume":"139","author":"Thithapandha","year":"1972","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib412","series-title":"Atlas of neuroactive substances and their receptors in the rat","author":"Tohyama","year":"1998"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib378","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/syn.20011","article-title":"Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with l-DOPA","volume":"52","author":"Tomiyama","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib380","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1212\/01.WNL.0000095222.41066.5E","article-title":"Sleep regulation in adenosine A2A receptor-deficient mice","volume":"61","author":"Urade","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib381","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002130000493","article-title":"Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies","volume":"151","author":"Vanderschuren","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib382","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1212\/WNL.42.8.1453","article-title":"Parkinson's disease in twins","volume":"42","author":"Vieregge","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib383","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/WNL.53.3.566","article-title":"Parkinson's disease in twins: a follow-up study","volume":"53","author":"Vieregge","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib384","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(03)00337-9","article-title":"Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats","volume":"346","author":"Villanueva-Toledo","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib385","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0003-4975(99)01018-8","article-title":"Broad-spectrum cardioprotection with adenosine","volume":"68","author":"Vinten-Johansen","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib386","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(94)90523-1","article-title":"Adenosine A3 receptor stimulation and cerebral ischemia","volume":"263","author":"Von Lubitz","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib387","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0014-2999(95)00498-X","article-title":"Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist","volume":"287","author":"Von Lubitz","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib388","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1124\/jpet.103.057083","article-title":"Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation","volume":"308","author":"Vortherms","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib389","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/jm0498405","article-title":"Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2A receptor antagonists","volume":"47","author":"Vu","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib390","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0304-3940(90)90137-X","article-title":"Effects of enucleations and visual deprivation on adenosine A1 and A2 receptor binding in superior colliculus of rat","volume":"117","author":"Wan","year":"1990","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib391","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0166-4328(03)00036-6","article-title":"Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor","volume":"143","author":"Wang","year":"2003","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib392","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0306-4522(98)00364-9","article-title":"Molecular and behavioral effects mediated by Gs-coupled adenosine A2A, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration","volume":"89","author":"Ward","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib393","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/WNL.33.7.815","article-title":"Parkinson's disease in 65 pairs of twins and in a set of quadruplets","volume":"33","author":"Ward","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib394","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/syn.1070","article-title":"SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats","volume":"41","author":"Wardas","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib395","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-003-1439-5","article-title":"Influence of CGS 21680, a selective adenosine A(2A) agonist, on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats","volume":"168","author":"Wardas","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib396","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0006-8993(03)02759-8","article-title":"SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum","volume":"977","author":"Wardas","year":"2003","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib397","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0169-328X(93)90058-W","article-title":"A2A adenosine receptor gene expression in developing rat brain","volume":"20","author":"Weaver","year":"1993","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib398","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1212\/01.WNL.0000095221.30476.8A","article-title":"Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation","volume":"61","author":"Weiss","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib399","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1212\/01.WNL.0000095581.20961.7D","article-title":"Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease","volume":"61","author":"Weiss","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib400","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1046\/j.0953-816x.2001.01743.x","article-title":"Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease","volume":"14","author":"Westin","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib401","first-page":"9","article-title":"Functional neuroanatomy of the basal ganglia in Parkinson's disease","volume":"91","author":"Wichmann","year":"2003","journal-title":"Adv Neurol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib422","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib402","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1212\/01.WNL.0000129841.30587.9D","article-title":"No evidence for heritability of Parkinson disease in Swedish twins","volume":"63","author":"Wirdefeldt","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib403","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjp.0703234","article-title":"Inhibition by adenosine A(2A) receptors of NMDA but not AMPA currents in rat neostriatal neurons","volume":"130","author":"Wirkner","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib404","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.neuropharm.2004.01.008","article-title":"Adenosine A2A receptor-induced inhibition of NMDA and GABAA receptor-mediated synaptic currents in a subpopulation of rat striatal neurons","volume":"46","author":"Wirkner","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib405","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0301-0082(97)00090-7","article-title":"The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants","volume":"54","author":"Wolf","year":"1998","journal-title":"Progr Neurobiol"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib406","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0304-3940(02)00069-1","article-title":"Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice","volume":"322","author":"Xu","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib407","series-title":"Program No. 487.5. 2002 Abstract viewer\/itinerary planner","article-title":"Neuroprotection by metabolites of caffeine may prolong its neuroprotection in the MPTP model of Parkinson's disease","author":"Xu","year":"2002"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib408","series-title":"Program No. 300.17. 2003 Abstract viewer\/itinerary planner","article-title":"Estrogen modulates neuroprotection by caffeine in the MPTP model of Parkinson's disease","author":"Xu","year":"2003"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib421","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0306-4522(94)00574-O","article-title":"Chronic l-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat","volume":"66","author":"Zeng","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib410","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1046\/j.1460-9568.2000.00988.x","article-title":"Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l-DOPA","volume":"12","author":"Zeng","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.10.007_bib411","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(90)90601-2","article-title":"Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release","volume":"180","author":"Zetterstrom","year":"1990","journal-title":"Eur J Pharmacol"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804001883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804001883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T21:35:44Z","timestamp":1682890544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725804001883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":425,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0163725804001883"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2004.10.007","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}